ATE514424T1 - Pharmazeutische zubereitungen von taxanen - Google Patents

Pharmazeutische zubereitungen von taxanen

Info

Publication number
ATE514424T1
ATE514424T1 AT00903178T AT00903178T ATE514424T1 AT E514424 T1 ATE514424 T1 AT E514424T1 AT 00903178 T AT00903178 T AT 00903178T AT 00903178 T AT00903178 T AT 00903178T AT E514424 T1 ATE514424 T1 AT E514424T1
Authority
AT
Austria
Prior art keywords
taxans
pharmaceutical preparations
formulation
methylpyrrolidin
docetaxel
Prior art date
Application number
AT00903178T
Other languages
English (en)
Inventor
Frederick Hausheer
Dhanabalan Murali
Original Assignee
Bionumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionumerik Pharmaceuticals Inc filed Critical Bionumerik Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE514424T1 publication Critical patent/ATE514424T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
AT00903178T 1999-01-08 2000-01-07 Pharmazeutische zubereitungen von taxanen ATE514424T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/226,968 US6040330A (en) 1999-01-08 1999-01-08 Pharmaceutical formulations of taxanes
PCT/US2000/000442 WO2000040238A1 (en) 1999-01-08 2000-01-07 Pharmaceutical formulations of taxanes

Publications (1)

Publication Number Publication Date
ATE514424T1 true ATE514424T1 (de) 2011-07-15

Family

ID=22851219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00903178T ATE514424T1 (de) 1999-01-08 2000-01-07 Pharmazeutische zubereitungen von taxanen

Country Status (9)

Country Link
US (1) US6040330A (de)
EP (1) EP1061915B1 (de)
JP (2) JP5642913B2 (de)
CN (1) CN1169525C (de)
AT (1) ATE514424T1 (de)
AU (1) AU764626B2 (de)
CA (1) CA2321826C (de)
DK (1) DK1061915T3 (de)
WO (1) WO2000040238A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004536026A (ja) 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
WO2002072150A2 (en) * 2001-03-13 2002-09-19 Angiotech Pharmaceuticals Inc. Micellar drug delivery vehicles and uses thereof
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
ATE363898T1 (de) 2001-04-20 2007-06-15 Univ British Columbia Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
AU2002329842B2 (en) * 2001-08-29 2006-09-14 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
WO2003045326A2 (en) * 2001-11-26 2003-06-05 Supergen, Inc Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
CN1303994C (zh) * 2003-03-03 2007-03-14 浙江海正药业股份有限公司 紫杉醇囊泡注射剂及其制备方法
WO2005007129A2 (en) * 2003-07-17 2005-01-27 Angiotech International Ag Topical formulations with bioactive components
ES2325506T3 (es) * 2003-12-12 2009-09-07 Quiral Quimica Do Brasil Procedimiento para la preparacion de principios activos farmaceuticos (api) anhidros e hidratados; composiciones farmaceuticas estables preparadas a partir de los mismos y usos de dichas composiciones.
US20050129719A1 (en) * 2003-12-15 2005-06-16 Yu-Fang Hu Concentrated emulsion formulation for silatecan
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
WO2006036969A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Formation of barrier layer
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) * 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US8312836B2 (en) * 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
WO2006036982A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US9801982B2 (en) * 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
EP1888137A2 (de) * 2005-04-29 2008-02-20 Atrium Medical Corporation Arzneistoffzuführungsbeschichtung zur verwendung mit einer medizinischen vorrichtung sowie verfahren zur behandlung von gefässverletzung
US20090118354A1 (en) * 2005-06-17 2009-05-07 Mayne Pharma Limited Liquid Pharmaceutical Formulations of Docetaxel
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
AU2006304590A1 (en) * 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
WO2007134354A1 (de) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmazeutische formulierung
ES2725023T3 (es) 2006-10-12 2019-09-18 Galera Labs Llc Métodos para el tratamiento de la mucositis oral
WO2008057328A2 (en) * 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9492596B2 (en) * 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
WO2009047794A2 (en) * 2007-10-01 2009-04-16 Intas Pharmaceuticals Limited Taxane derivative composition
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
CA2781529C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US9724329B2 (en) * 2010-06-21 2017-08-08 Peter Maccallum Cancer Institute Stimulating immune response
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US20120172796A1 (en) 2010-12-30 2012-07-05 Chappa Ralph A Composition for intravascular delivery of therapeutic composition
JP2013032332A (ja) * 2011-07-01 2013-02-14 Lintec Corp 免疫賦活剤
CN103906756B (zh) * 2011-09-26 2020-03-03 加莱拉实验室有限责任公司 用于治疗疾病的方法
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
EP2777691A1 (de) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Reinigung der flüssigen Hilfsstoffen
HUE049926T2 (hu) 2015-08-11 2020-11-30 Galera Labs Llc Makrociklusos pentaazagyûrûkomplexek orális biológiai hozzáférhetõséggel
IL295620B2 (en) 2017-04-13 2024-01-01 Galera Labs Llc Cancer immunotherapy combined with a macrocyclic ring pentase complex
CN107157926B (zh) * 2017-07-20 2020-08-21 四川汇宇制药股份有限公司 一种多西他赛注射剂的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
EP1500393A1 (de) * 1992-11-27 2005-01-26 Mayne Pharma (USA) Inc. Injizierbare Arzneizubereitung welche Taxol enthält
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5554382A (en) * 1993-05-28 1996-09-10 Aphios Corporation Methods and apparatus for making liposomes
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6630168B1 (en) * 1997-02-20 2003-10-07 Biomedicines, Inc. Gel delivery vehicles for anticellular proliferative agents
HU230338B1 (hu) * 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
PL191780B1 (pl) * 1997-07-29 2006-07-31 Upjohn Co Kompozycja farmaceutyczna w postaci samoemulgującej formulacji związków lipofilowych i samoemulgujące podłoże formulacji
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes

Also Published As

Publication number Publication date
CN1293570A (zh) 2001-05-02
EP1061915A1 (de) 2000-12-27
US6040330A (en) 2000-03-21
EP1061915B1 (de) 2011-06-29
JP5642913B2 (ja) 2014-12-17
JP2002534382A (ja) 2002-10-15
CN1169525C (zh) 2004-10-06
AU764626B2 (en) 2003-08-28
JP2010235636A (ja) 2010-10-21
EP1061915A4 (de) 2009-09-09
CA2321826A1 (en) 2000-07-13
CA2321826C (en) 2007-12-04
WO2000040238A1 (en) 2000-07-13
AU2496300A (en) 2000-07-24
JP5285663B2 (ja) 2013-09-11
DK1061915T3 (da) 2011-10-03

Similar Documents

Publication Publication Date Title
ATE514424T1 (de) Pharmazeutische zubereitungen von taxanen
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
ECSP045411A (es) Derivados de quinolinona
CA2301057A1 (en) A method of administering liposomal encapsulated taxane
DE60030844D1 (de) Kombinationen von formoterol und tiotropium-salz
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
ATE113481T1 (de) Immunokonjugate und prodrogen und ihre gemeinschaftliche anwendung für die verabreichung von arzneimitteln.
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
HUP0102033A2 (hu) PEG IFN-alfa és ribavirin felhasználása krónikus hepatitis C kezelésére
ES2190692B1 (es) Formulacion farmaceutica de amoxicilina y clavulanato de potasio.
ATE292453T1 (de) Antivirale arznei
ATE329903T1 (de) Hochgradig lipophile camptothecin-derivate
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
HK1068606A1 (en) Novel aminobenzoephenones
BG66113B1 (bg) Комбиниран химиотерапевтичен състав
HUP0203716A2 (hu) Tumorellenes hatású szubsztituált (N-benzil-indol-3-il)-glioxilsav-származékok, ezeket tartalmazó gyógyszerkészítmények
HUP0003546A2 (hu) Kompozíciók taxánok orális adagolására embereknek
DE60045114D1 (de) Zubereitungen zur Erhöhung der Bioverfügbarkeit von oral verabreichten pharmazeutischen Verbindungen
ATE311904T1 (de) Halbfester verabreichungsträger und arzneimittel
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
PE20010407A1 (es) Formulacion farmaceutica en capsulas de hidroxipropilmetilcelulosa
WO2002078690A3 (en) Taxoid anti-tumor agents and pharmaceutical compositions thereof
Yeh et al. Ritonavir-boosted atazanavir, lopinavir, & darunavir increase HCV NS5A inhibitor MK-8742 levels
CA2385755A1 (en) Prevention of colorectal cancer
WO2004071398A3 (en) Pharmaceutical patch

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1061915

Country of ref document: EP